Nasal spray monograph petition denied
This article was originally published in The Tan Sheet
Executive Summary
FDA rejects a petition submitted by SinoFresh Research Labs to include nasal sprays containing .05% cetylpyridinium chloride in the tentative final monograph for Oral Antiseptic Drug Products. The agency panel did not consider nasal antiseptics when it evaluated OTC oral antiseptics, FDA states. Consequently, the firm's nasal and sinus care product is an unapproved new drug due to insufficient marketing history. The agency also concludes safety and efficacy data provided by the Venice, Fla. firm is inadequate. SinoFresh petitioned to reopen the administrative record for the monograph to allow for additional data in March 2003 1("The Tan Sheet" April 7, 2003, p. 7)...
You may also be interested in...
Cetylpyridinium Nasal Spray Status As Category I Oral Antiseptic Requested
Inclusion of a nasal spray containing .05% cetylpyridinium chloride in FDA's tentative final monograph for Oral Antiseptic Drug Products is requested by SinoFresh Research Labs in a March 24 citizen petition
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.